Clinical evidence summary Pacaediatric Gut Health & the 35624™ Probiotic Strain

The gut microbiome plays a key role in paediatric gastrointestinal health and is increasingly recognised as a factor in disorders of gut-brain interaction (DGBIs), including irritable bowel syndrome (IBS). This clinical evidence summary reviews the latest research on Bifidobacterium longum 35624™, including its proposed immunomodulatory mechanisms, clinical guideline recognition, and emerging evidence in children and adolescents with IBS.

Developed for healthcare professionals, the report examines clinical and real-world data evaluating the impact of B. longum 35624™ on IBS symptom severity, abdominal pain, bloating, bowel habit satisfaction, quality of life, and everyday functioning. It also explores the growing understanding of the paediatric gut microbiome and the rationale for targeted probiotic interventions in paediatric IBS management.

• Clinical evidence for Bifidobacterium longum 35624™ in paediatric IBS, including studies in children and adolescents with symptoms consistent with disorders of gut-brain interaction.
• Insights into the paediatric gut microbiome and IBS, highlighting the role of microbiota composition, gut-brain interactions, and immune function.
• Review of international guidelines and expert recommendations supporting the use of specific probiotic strains in children with IBS symptoms.
• Evidence on key patient-relevant outcomes, including abdominal pain, bloating, bowel habits, impact on daily life, school attendance, and wellbeing.
• Mechanistic and safety data for B. longum 35624™, including immunoregulatory pathways and studies demonstrating tolerability in paediatric populations.